These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1048 related articles for article (PubMed ID: 35847972)

  • 21. A comprehensive study based on exosome-related immunosuppression genes and tumor microenvironment in hepatocellular carcinoma.
    Yang Z; Li X; Pan C; Li Y; Lin L; Jin Y; Zheng J; Yu Z
    BMC Cancer; 2022 Dec; 22(1):1344. PubMed ID: 36550445
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Construction of a Novel LncRNA Signature Related to Genomic Instability to Predict the Prognosis and Immune Activity of Patients With Hepatocellular Carcinoma.
    Zhu J; Huang Q; Liu S; Peng X; Xue J; Feng T; Huang W; Chen Z; Lai K; Ji Y; Wang M; Yuan R
    Front Immunol; 2022; 13():856186. PubMed ID: 35479067
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of prognostic immune-related gene signature associated with tumor microenvironment of colorectal cancer.
    Wang Y; Li W; Jin X; Jiang X; Guo S; Xu F; Su X; Wang G; Zhao Z; Gu X
    BMC Cancer; 2021 Aug; 21(1):905. PubMed ID: 34364366
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification and Validation of Necroptosis-Related LncRNA Signature in Hepatocellular Carcinoma for Prognosis Estimation and Microenvironment Status.
    Chen C; Wu Y; Chen K; Xia Z; Liu X; Zhang C; Zhao H; Shen A
    Front Genet; 2022; 13():898507. PubMed ID: 35754846
    [No Abstract]   [Full Text] [Related]  

  • 25. Mitochondrial-Related Transcriptome Feature Correlates with Prognosis, Vascular Invasion, Tumor Microenvironment, and Treatment Response in Hepatocellular Carcinoma.
    Wang Y; Song F; Zhang X; Yang C
    Oxid Med Cell Longev; 2022; 2022():1592905. PubMed ID: 35535359
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune- and metabolism-related gene signature analysis uncovers the prognostic and immune microenvironments of hepatocellular carcinoma.
    Gu Y; Ma E; Jiang S; Shan Z; Xia G; Ma R; Fu J; Wang Z
    J Cancer Res Clin Oncol; 2024 Jun; 150(6):311. PubMed ID: 38896142
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of Prognostic Glycolysis-Related lncRNA Signature in Tumor Immune Microenvironment of Hepatocellular Carcinoma.
    Bai Y; Lin H; Chen J; Wu Y; Yu S
    Front Mol Biosci; 2021; 8():645084. PubMed ID: 33968985
    [No Abstract]   [Full Text] [Related]  

  • 28. Comprehensive
    Xu T; Xu W; Zheng Y; Li X; Cai H; Xu Z; Zou Q; Yu B
    Front Immunol; 2022; 13():931906. PubMed ID: 35958598
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification and Validation of a Novel Tertiary Lymphoid Structures-Related Prognostic Gene Signature in Hepatocellular Carcinoma.
    Liu Y; Li CB; Zhai YP; Zhang SK; Li DY; Gao ZQ; Liang RP
    World J Oncol; 2024 Aug; 15(4):695-710. PubMed ID: 38993245
    [TBL] [Abstract][Full Text] [Related]  

  • 30. N6-Methyladenine-Related Signature for Immune Microenvironment and Response to Immunotherapy in Hepatocellular Carcinoma.
    Ren SH; Qin YF; Qin H; Wang HD; Li GM; Zhu YL; Sun CL; Shao B; Zhang JY; Hao JP; Wang H
    Int J Gen Med; 2022; 15():3525-3540. PubMed ID: 35386863
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of a prognostic and therapeutic immune signature associated with hepatocellular carcinoma.
    Peng Y; Liu C; Li M; Li W; Zhang M; Jiang X; Chang Y; Liu L; Wang F; Zhao Q
    Cancer Cell Int; 2021 Feb; 21(1):98. PubMed ID: 33568167
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic Value of Cancer-Associated Fibroblast-Related Gene Signatures in Hepatocellular Carcinoma.
    Dong W; Xie Y; Huang H
    Front Endocrinol (Lausanne); 2022; 13():884777. PubMed ID: 35733776
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An Intratumor Heterogeneity-Related Signature for Predicting Prognosis, Immune Landscape, and Chemotherapy Response in Colon Adenocarcinoma.
    Liu C; Liu D; Wang F; Xie J; Liu Y; Wang H; Rong J; Xie J; Wang J; Zeng R; Zhou F; Xie Y
    Front Med (Lausanne); 2022; 9():925661. PubMed ID: 35872794
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of molecular subtypes based on PANoptosis-related genes and construction of a signature for predicting the prognosis and response to immunotherapy response in hepatocellular carcinoma.
    Zhu J; Huang Q; Peng X; Luo C; Liu Z; Liu D; Yuan H; Yuan R; Cheng X
    Front Immunol; 2023; 14():1218661. PubMed ID: 37662906
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Integrative transcriptional characterization of cell cycle checkpoint genes promotes clinical management and precision medicine in bladder carcinoma.
    Shi WW; Guan JZ; Long YP; Song Q; Xiong Q; Qin BY; Ma ZQ; Hu Y; Yang B
    Front Oncol; 2022; 12():915662. PubMed ID: 36033441
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pyroptosis related genes signature predicts prognosis and immune infiltration of tumor microenvironment in hepatocellular carcinoma.
    Fang G; Zhang Q; Fan J; Li H; Ding Z; Fu J; Wu Y; Zeng Y; Liu J
    BMC Cancer; 2022 Sep; 22(1):999. PubMed ID: 36127654
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification and validation of a dysregulated TME-related gene signature for predicting prognosis, and immunological properties in bladder cancer.
    Shen C; Chai W; Han J; Zhang Z; Liu X; Yang S; Wang Y; Wang D; Wan F; Fan Z; Hu H
    Front Immunol; 2023; 14():1213947. PubMed ID: 37965307
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of fatty acid metabolism-related molecular subtype biomarkers and their correlation with immune checkpoints in cutaneous melanoma.
    Xu Y; Chen Y; Jiang W; Yin X; Chen D; Chi Y; Wang Y; Zhang J; Zhang Q; Han Y
    Front Immunol; 2022; 13():967277. PubMed ID: 36466837
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of prognostic alternative splicing events related to the immune microenvironment of hepatocellular carcinoma.
    Yu S; Cai L; Liu C; Gu R; Cai L; Zhuo L
    Mol Med; 2021 Apr; 27(1):36. PubMed ID: 33832428
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A m
    Xu S; Zhang Y; Yang Y; Dong K; Zhang H; Luo C; Liu SM
    Front Immunol; 2024; 15():1374465. PubMed ID: 39119345
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 53.